• MAIA Biotechnology activated first U.S. clinical site for its Phase 2 THIO-101 expansion trial testing ateganosine as third-line treatment for advanced non-small cell lung cancer.
• Trial expansion follows results already presented in 2025 that indicated outcomes above standard-of-care expectations in heavily pre-treated patients, including signs of durable benefit.
• Study is evaluating ateganosine alone or sequenced with Regeneron’s checkpoint inhibitor cemiplimab in patients who previously failed chemotherapy or checkpoint inhibitors.
• U.S. third-line evaluation is supported by an NIH grant of USD 2.3 million, positioning MAIA to broaden enrollment from its existing Europe and Asia footprint.
• Program holds FDA Fast Track designation, which could speed regulatory review if subsequent data support an accelerated pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief on April 16, 2026, and is solely responsible for the information contained therein.